The content on this site is intended for healthcare professionals only
Dr Stefania Oliva speaks to ecancer about minimum residual disease techniques in myeloma. Initially, she talks about the best techniques for measuring MRD in clinical practice and then she discusses the use of MRD in clinical trials.
Dr Oliva then talks about the different treatment methods that can be given to patients depending on whether they are MRD positive or negative. She concludes by saying that MRD should be used as a surrogate for survival in clinical trials.
Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM
Synthetic biology and precision medicine in blood and gynaecological cancers
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
OncoAlert Round Up for September 15-21, 2023
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
Choosing Wisely in multiple myeloma
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL
Systemic anti-cancer performance matrix
Redefining cancer research priorities in the emerging context of the COVID-19 pandemic
